Group 1: Company Performance - A total of 55 listed companies in the A-share market have forecasted their performance for the first half of 2025, with 39 companies expecting positive results, representing over 70% [1] - Shenzhen Hanyu Pharmaceutical Co., Ltd. anticipates a net profit of between 142 million to 162 million yuan for the first half of 2025, marking a year-on-year increase of 1470.82% to 1663.89% [1] - Chengdu Saintno Biological Technology Co., Ltd. expects a net profit of 77.03 million to 94.14 million yuan, reflecting a year-on-year growth of 253.54% to 332.10% due to strong performance in its peptide raw material business [1] Group 2: Industry Trends - The pharmaceutical sector is experiencing accelerated growth driven by "innovation + overseas expansion," with innovative drug companies enhancing their international market presence [2] - The electronic industry is benefiting from structural opportunities, particularly in hardware companies, with TaiLing Microelectronics forecasting a revenue of approximately 503 million yuan, a year-on-year increase of around 37%, and a net profit of about 99 million yuan, up 267% [2] - Anhui Xindong Lian Technology Co., Ltd. projects a net profit between 138 million to 169 million yuan for the first half of 2025, representing a growth of approximately 144.46% to 199.37% due to leading product performance and successful customer recognition [3]

股票简称：芯动联科 股票代码：688582 安徽芯动联科微系统股份有限公司 Anhui XDLK Microsystem Corporation Limited （安徽省蚌埠市财院路 10 号） 首次公开发行股票科创板 上市公告书 保荐人（主承销商） （北京市朝阳区安立路66号4号楼） 二零二三年六月二十九日 特别提示 安徽芯动联科微系统股份有限公司（以下简称"芯动联科"、"发行人"、 "本公司"或"公司"）股票将于 2023 年 6 月 30 日在上海证券交易所科创板 上市。本公司提醒投资者应充分了解股票市场风险及本公司披露的风险因素， 在新股上市初期切忌盲目跟风"炒新"，应当审慎决策、理性投资。 本上市公告书中所引用数据，如合计数与各分项数直接相加之和存在差异， 或小数点后尾数与原始数据存在差异，可能系由精确位数不同或四舍五入形成 的。 1 第一节 重要声明与提示 一、重要声明与提示 （一）本公司及全体董事、监事、高级管理人员保证上市公告书所披露信 息的真实、准确、完整，承诺上市公告书不存在虚假记载、误导性陈述或者重 大遗漏，并依法承担法律责任； （二）上海证券交易所、有关政府机关对本公司股票上市及有关事 ...